BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $124.00 at Morgan Stanley

BioMarin Pharmaceutical (NASDAQ:BMRN) had its target price boosted by Morgan Stanley from $119.00 to $124.00 in a report released on Friday,Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the company. Royal Bank Of Canada cut their price target on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 7th. Oppenheimer boosted their target price on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a research note on Friday. Canaccord Genuity Group reduced their target price on shares of BioMarin Pharmaceutical from $116.00 to $111.00 and set a “buy” rating on the stock in a report on Friday, May 22nd. Wall Street Zen cut shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Finally, Sanford C. Bernstein lowered their target price on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $87.86.

BioMarin Pharmaceutical Stock Performance

NASDAQ:BMRN opened at $63.81 on Friday. The firm’s fifty day simple moving average is $58.19 and its 200-day simple moving average is $57.06. The company has a quick ratio of 4.20, a current ratio of 5.81 and a debt-to-equity ratio of 0.23. The stock has a market cap of $12.33 billion, a PE ratio of 172.46, a price-to-earnings-growth ratio of 0.47 and a beta of 0.24. BioMarin Pharmaceutical has a fifty-two week low of $49.26 and a fifty-two week high of $66.28.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.36%. The firm had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. During the same quarter last year, the business earned $1.44 earnings per share. The business’s revenue for the quarter was up 20.0% compared to the same quarter last year. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Analysts expect that BioMarin Pharmaceutical will post 4.22 earnings per share for the current fiscal year.

Institutional Trading of BioMarin Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the business. Viking Global Investors LP increased its position in shares of BioMarin Pharmaceutical by 13.8% in the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after purchasing an additional 1,488,552 shares during the last quarter. Norges Bank bought a new position in BioMarin Pharmaceutical in the fourth quarter worth about $447,572,000. AQR Capital Management LLC boosted its position in BioMarin Pharmaceutical by 12.7% during the 4th quarter. AQR Capital Management LLC now owns 6,686,916 shares of the biotechnology company’s stock valued at $395,197,000 after purchasing an additional 754,807 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of BioMarin Pharmaceutical by 14.5% during the first quarter. Dimensional Fund Advisors LP now owns 3,802,930 shares of the biotechnology company’s stock valued at $214,804,000 after acquiring an additional 481,176 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of BioMarin Pharmaceutical by 3.7% during the fourth quarter. Geode Capital Management LLC now owns 3,674,089 shares of the biotechnology company’s stock worth $218,395,000 after acquiring an additional 131,969 shares during the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q2 results exceeded expectations. BioMarin reported adjusted earnings of $1.20 per share versus the $0.95–$0.96 analyst consensus, while revenue rose 20% year over year to approximately $990 million, ahead of estimates near $932 million. BioMarin Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 outlook. Full-year adjusted EPS guidance increased to $4.90-$5.10 from a prior level below that range and above the roughly $4.80 consensus. Revenue guidance was set around $3.9 billion. Stronger-than-expected VOXZOGO sales and continued momentum in key therapies supported the revision. BioMarin Reports Second Quarter 2026 Results
• Positive Sentiment: Amicus additions could improve long-term growth. BioMarin said the addition of GALAFOLD and POMBILITI plus OPFOLDA, along with cost synergies, should accelerate revenue growth, earnings accretion, operating-margin expansion and cash flow through the mid-2030s. BioMarin Lifts 2026 Outlook
• Positive Sentiment: Morgan Stanley raised its price target to $124 from $119 and maintained an Overweight rating, signaling substantial potential upside in its valuation view.
• Neutral Sentiment: HC Wainwright increased its target to $60 from $50 but retained a Neutral rating, indicating more cautious expectations than Morgan Stanley.
• Negative Sentiment: BioMarin discontinued a $270 million rare-disease asset after the treatment missed its Phase 3 endpoint. The setback removes a potential growth opportunity and highlights clinical-development risk. BioMarin Axes Rare-Disease Asset

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.